Article info
PDFEditorial
Aducanumab for Alzheimer’s disease: expediting approval and delaying science
- Correspondence to Dr Rodrigo A. Salinas, Departamento de Ciencias Neurológicas, Universidad de Chile, Santiago de Chile, RM 7500922, Chile; salinasra{at}gmail.com
Citation
Aducanumab for Alzheimer’s disease: expediting approval and delaying science
Publication history
- Accepted June 21, 2021
- First published July 14, 2021.
Online issue publication
January 10, 2022
Article Versions
- Previous version (10 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.